Dr. Rosen describes the treatment options for non-Hodgkin lymphoma/NHL.
The majority of individuals who are diagnosed with a non-Hodgkin’s lymphoma will receive chemotherapy at some juncture, not universal, but the majority. In addition to chemotherapy, we now have a number of biologic treatments that are being applied to the treatment of these diseases. We use the term biologic in contrast to chemotherapy for agents that actually target a specific pathway that’s involved in the replication of the cancer cell or, in some instances, an antibody that binds to the surface of the cancer cell and kills the cancer cell.
So often a combination of chemotherapy and biologic therapy is used to treat these disorders. There were some instances where a biologic therapy alone is sufficient to control the disease for many years.
About Dr. Steven Rosen, M.D., F.A.C.P:
Steven Rosen, M.D., F.A.C.P., is Genevieve Teuton Professor of Medicine, at the Feinberg School of Medicine, Northwestern University and Director of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University and Director of Cancer Programs at Northwestern Memorial Hospital. Following his graduation with distinction from Northwestern University Medical School's Six-Year Honors Program in 1976, Dr. Rosen completed his residency in Internal Medicine at Northwestern and a fellowship in Medical Oncology at the National Cancer Institute. Dr. Rosen's laboratory research focuses on experimental therapeutics and hematologic malignancies.